AU2022384597B2 - Antibody molecules and conjugates - Google Patents

Antibody molecules and conjugates

Info

Publication number
AU2022384597B2
AU2022384597B2 AU2022384597A AU2022384597A AU2022384597B2 AU 2022384597 B2 AU2022384597 B2 AU 2022384597B2 AU 2022384597 A AU2022384597 A AU 2022384597A AU 2022384597 A AU2022384597 A AU 2022384597A AU 2022384597 B2 AU2022384597 B2 AU 2022384597B2
Authority
AU
Australia
Prior art keywords
amino acid
region
egfr
antibody molecule
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022384597A
Other languages
English (en)
Other versions
AU2022384597A1 (en
Inventor
Andrew Grier Buchanan
Frank Irvine COMER
Qun DU
Srinath Kasturirangan
Yariv Mazor
Chunning YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2022384597A1 publication Critical patent/AU2022384597A1/en
Application granted granted Critical
Publication of AU2022384597B2 publication Critical patent/AU2022384597B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022384597A 2021-11-10 2022-11-09 Antibody molecules and conjugates Active AU2022384597B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163263835P 2021-11-10 2021-11-10
US63/263,835 2021-11-10
PCT/EP2022/081225 WO2023083846A1 (en) 2021-11-10 2022-11-09 Antibody molecules and conjugates

Publications (2)

Publication Number Publication Date
AU2022384597A1 AU2022384597A1 (en) 2024-06-13
AU2022384597B2 true AU2022384597B2 (en) 2026-05-07

Family

ID=84387847

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022384597A Active AU2022384597B2 (en) 2021-11-10 2022-11-09 Antibody molecules and conjugates

Country Status (15)

Country Link
US (2) US12065496B2 (cg-RX-API-DMAC7.html)
EP (1) EP4429765A1 (cg-RX-API-DMAC7.html)
JP (1) JP7861115B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240099430A (cg-RX-API-DMAC7.html)
CN (1) CN118556084A (cg-RX-API-DMAC7.html)
AR (1) AR127629A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022384597B2 (cg-RX-API-DMAC7.html)
CA (1) CA3237211A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001384A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024007192A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP24044371A (cg-RX-API-DMAC7.html)
IL (1) IL312566A (cg-RX-API-DMAC7.html)
MX (1) MX2024005712A (cg-RX-API-DMAC7.html)
TW (1) TW202336037A (cg-RX-API-DMAC7.html)
WO (1) WO2023083846A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525410A (ja) * 2022-06-27 2025-08-05 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮成長因子受容体チロシンキナーゼ阻害剤を伴う組み合わせ
CN122161833A (zh) * 2023-11-15 2026-06-05 四川科伦博泰生物医药股份有限公司 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
IL328594A (en) 2023-11-23 2026-07-01 Velavigo Bio Inc Binding molecule and antibody-drug conjugate and their uses
CN117659203B (zh) * 2023-12-06 2024-08-13 科弈(浙江)药业科技有限公司 一种抗met/egfr双特异性抗体及其药物偶联物
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途
TW202608928A (zh) * 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體藥物偶聯物
TW202608927A (zh) * 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體-藥物偶聯物
WO2026021476A1 (en) 2024-07-24 2026-01-29 Beone Guangzhou Biologics Manufacturing Co., Ltd. Anti-cmet and anti-egfr multispecific antibody drug conjugates
CN121868507A (zh) * 2024-10-16 2026-04-17 上海安领科生物医药有限公司 抗EGFR和cMET双特异性抗体的抗体药物偶联物
WO2026086737A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Uses and methods of bispecific antibody-drug conjugates for treating tumor diseases
WO2026086740A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use and method of bispecific antibody-drug conjugates for treating tumor diseases
WO2026086844A1 (zh) * 2024-10-23 2026-04-30 正大天晴药业集团股份有限公司 靶向EGFR和c-Met的抗体药物偶联物
WO2026098440A1 (zh) * 2024-11-05 2026-05-15 上海齐鲁制药研究中心有限公司 一种双特异性抗体偶联物及其制备方法和应用
WO2026124468A1 (en) * 2024-12-10 2026-06-18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Pharmaceutical combinations, their uses and therapeutic methods
WO2026145588A1 (en) 2024-12-31 2026-07-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use of egfr/c-met bispecific binding protein
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2026150367A1 (en) * 2025-01-13 2026-07-16 Janssen Biotech, Inc. Bispecific anti-egfr/c-met antibody-drug conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017076492A1 (en) * 2015-11-03 2017-05-11 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
US20200231681A1 (en) * 2017-05-30 2020-07-23 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-met antibody and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP1521769B1 (de) 2002-07-09 2015-09-09 Dömling, Alexander Tubulysinkonjugate
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
US8889880B2 (en) 2010-08-06 2014-11-18 Endocyte, Inc. Processes for preparing tubulysins
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
CA2945318A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Tubulysin derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017076492A1 (en) * 2015-11-03 2017-05-11 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
US20200231681A1 (en) * 2017-05-30 2020-07-23 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-met antibody and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J M LEE ET AL: "Novel strategy for a bispecific antibody: induction of dual target internalization and degradation", ONCOGENE, vol. 35, no. 34, 8 February 2016 (2016-02-08), London, pages 4437 - 4446. *
MARCEL RIEKER: "Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2- Duocarmycin Antibody-Drug Conjugates Combined with", 1 Jan2018. *
SELLMANN CAROLIN ET AL: "Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates", J BIOL CHEM, vol. 291, no. 48, 1 Nov 2016, US, pages 25106 - 25119. *

Also Published As

Publication number Publication date
ECSP24044371A (es) 2024-07-31
JP7861115B2 (ja) 2026-05-18
US12065496B2 (en) 2024-08-20
WO2023083846A1 (en) 2023-05-19
IL312566A (en) 2024-07-01
US20230183358A1 (en) 2023-06-15
EP4429765A1 (en) 2024-09-18
CL2024001384A1 (es) 2024-08-23
CN118556084A (zh) 2024-08-27
JP2024544520A (ja) 2024-12-03
US20240360226A1 (en) 2024-10-31
TW202336037A (zh) 2023-09-16
KR20240099430A (ko) 2024-06-28
AU2022384597A1 (en) 2024-06-13
MX2024005712A (es) 2024-05-24
AR127629A1 (es) 2024-02-14
CA3237211A1 (en) 2023-05-19
CO2024007192A2 (es) 2024-07-18

Similar Documents

Publication Publication Date Title
US12065496B2 (en) Antibody molecules and conjugates
JP7118117B2 (ja) 抗体-薬物コンジュゲートの選択的製造方法
TWI854047B (zh) 抗人Trop-2抗體及其應用
KR20220075396A (ko) Cldn18.2를 표적으로 하는 항체, 이의 제조 방법 및 이의 용도
CA3005294A1 (en) Anti-5t4 antibodies and antibody-drug conjugates
JP2021521872A (ja) C−metに特異的に結合する抗体及びその用途
EP4543920A1 (en) Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
EP4534103A1 (en) Pharmaceutical composition of recombinant anti-human cldn18.2 monoclonal antibody-mmae conjugate
WO2026086737A1 (en) Uses and methods of bispecific antibody-drug conjugates for treating tumor diseases
WO2025242845A1 (en) Colorectal cancer treatment
HK40086745A (en) Method for selectively manufacturing antibody-drug conjugate